^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Cholangiocarcinoma

Related cancers:
1d
Biliary concentration of CA19-9 and CA125, iron metabolism markers, and PIVKA-II activity in pancreatobiliary tumors. (PubMed, Dig Dis)
CA125 and hepcidin as quantitative markers, along with PIVKA-II as a qualitative marker, demonstrate significant potential as biliary markers for distinguishing choledocholithiasis from biliary tract or pancreatic cancers. Biliary iron, TIBC, and CA19-9 require further investigation to confirm their diagnostic yield.
Journal
|
CA 19-9 (Cancer antigen 19-9)
1d
Right-side versus left-side hemihepatectomy for the treatment of Bismuth type IV perihilar cholangiocarcinoma: a comparative study. (PubMed, Front Oncol)
The postoperative morbidity and mortality rate was comparable between LH and RH for Bismuth type IV PHC. Although RH showed a favorable survival from the Kaplan-Meier survival curve, no significant difference was observed in overall survival after LH versus RH for the overall cohort and the matched cohort after PSM.
Journal
|
CA 19-9 (Cancer antigen 19-9)
2d
Intravital Microscopy in Human Solid Tumors (clinicaltrials.gov)
P=N/A, N=85, Recruiting, Mayo Clinic | Trial completion date: May 2026 --> Sep 2026 | Trial primary completion date: May 2026 --> Sep 2026
Trial completion date • Trial primary completion date
2d
E3 Ubiquitin Ligase TRIM47 Promotes Intrahepatic Cholangiocarcinoma Progression by Ubiquitinating Fumarate Hydratase and Modulating Macrophage Polarization. (PubMed, J Biol Chem)
FH overexpression restored the effects of TRIM47. Collectively, the observations demonstrate that TRIM47 accelerates the progression of ICC by interacting with FH and ubiquitinating FH, indicating that TRIM47/FH axis may be potential target for ICC treatment.
Journal
|
FH (Fumarate Hydratase) • TRIM4 (Tripartite Motif Containing 4) • TRIM47 (Tripartite Motif Containing 47)
3d
MicroRNA-1 Suppresses Tumor Progression and UHRF1 Expression in Cholangiocarcinoma. (PubMed, Int J Mol Sci)
This study demonstrated that cholangiocarcinoma progression was suppressed by restoring miR-1 expression, suggesting that UHRF1 expression is involved in cholangiocarcinoma progression. The results of this study provide new insights into the molecular mechanisms underlying cholangiocarcinoma progression.
Journal
|
UHRF1 (Ubiquitin Like With PHD And Ring Finger Domains 1)
3d
A Comprehensive Analysis of Novel Variations Associated with Bile Duct Cancer: Insights into Expression, Methylation, and 3D Protein Structure. (PubMed, Int J Mol Sci)
This multi-omics, public data-driven synthesis delineates a coherent network of genomic, epigenomic, transcriptomic, and structural vulnerabilities, offering a rational framework for therapeutic targeting of cholangiocarcinoma. This study reveals novel bile duct-associated variations that expand our understanding of cholangiocarcinoma pathogenesis and provide potential targets for precision medicine approaches.
Journal
|
MAP2K1 (Mitogen-activated protein kinase kinase 1) • TUBB3 (Tubulin beta 3 class III) • ABCA1 (ATP Binding Cassette Subfamily A Member 1) • FLNC (Filamin C)
3d
Spatiotemporal landscape of intrahepatic cholangiocarcinoma liver metastasis at the single-cell level. (PubMed, Hepatology)
We revealed the key biological mechanisms involved in the invasion and colonization phases of iCCA liver metastasis. Moreover, we provide valuable data for understanding iCCA liver metastasis and a possible avenue for the treatment of advanced iCCA.
Journal
|
COL3A1 (Collagen Type III Alpha 1 Chain)
4d
Mesothelin in solid tumors: biology, biomarker utility, and therapeutic targeting. (PubMed, Curr Opin Obstet Gynecol)
MSLN is expressed in solid tumor patients, with no differences in expression among histologies. MSLN expression is associated with Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) stage and platinum sensitivity. Higher MSLN expression is detected among primary ovarian cancer patients and correlates with better survival data in HGSOC patients only. According to our data, treatment strategies targeting MSLN should be offered in first line setting rather than in relapse.
Journal
|
MSLN (Mesothelin) • MUC16 (Mucin 16, Cell Surface Associated)
4d
Exploratory study on the role of Clonorchis sinensis infection in promoting cholangiocarcinoma progression. (PubMed, Parasit Vectors)
C. sinensis can effectively promote the pathogenesis of CCA and significantly increase the expression of CCA-related genes (e.g., CK19 and CK7). The inflammation, disrupting circadian rhythms and altering energy metabolism caused by C. sinensis infection, may promote the progression of CCA. This study provides a foundational experimental basis for diagnosing and intervening in C. sinensis-related CCA.
Journal
|
TP53 (Tumor protein P53) • MMP2 (Matrix metallopeptidase 2) • KRT19 (Keratin 19) • PCNA (Proliferating cell nuclear antigen) • ITGB1 (Integrin Subunit Beta 1)
5d
ELEGANCE: Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN (clinicaltrials.gov)
P=N/A, N=60, Recruiting, Nantes University Hospital | Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2027 --> May 2027
Enrollment open • Trial primary completion date
|
CA9 (Carbonic anhydrase 9)
5d
Trop2-targeted immunoPET Imaging of Solid Tumors (clinicaltrials.gov)
P2/3, N=400, Recruiting, RenJi Hospital | Phase classification: P=N/A --> P2/3
Phase classification